Condition: C3 Glomerulopathy · Idiopathic Immune Complex-Mediated Glomerulonephritis · Sponsor: Omeros Corporation
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)
This description comes directly from the study's public registry record.
Omeros Clinical Trial Information · 206-676-5000 · ctinfo@omeros.com
Always discuss trial participation with your own doctor first.
| Omeros Investigational Site | Kaunas, Lithuania | Recruiting |
| Omeros Investigational Site | Vilnius, Lithuania | Recruiting |
| Omeros Investigational Site | Auckland, New Zealand | Recruiting |
| Omeros Investigational Site | Lodz, Poland | Recruiting |
| Omeros Investigational Site | Leicester, United Kingdom | Recruiting |
| Omeros Investigational Site | Newcastle upon Tyne, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06209736